Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. Nick Colangelo, president and CEO will present
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Needham
CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2019 financial results and
Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a
MACI Revenue Increased 38% Over First Quarter 2018 Positive Cash Flow in First Quarter Announced Exclusive License Agreement with MediWound for North American Rights to NexoBrid Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 UBS Global
NexoBrid Expanded Access Treatment Protocol (NEXT) to Start in the Third Quarter of 2019, Allowing for the Treatment of up to 150 Burn Patients at 30 Sites in the United States CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for
CAMBRIDGE, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2019 financial results and
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 39 th Annual Canaccord
Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation
